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Most women feel confident taking the modern combined oestrogen-progestogen oral contraceptive pill (COCPs) but myths 
about these drugs still persist. Most non-contraceptive health benefits of COCPs are not widely appreciated, in spite of much 
evidence. Controversy still exists over the association between COCP use and breast cancer. Although slightly more breast 
cancers are detected in current COCP users they are less advanced in stage and less aggressive in behaviour. This article 
discusses the non-contraceptive benefits and uses of hormonal contraception.
Introduction
The combined oestrogen-progestogen 
oral contraceptive pill (COCP) was first 
marketed for the treatment of menstru-
al disturbances, in 1957 in the United 
States.1  With the increasing popularity 
of “the pill” for contraception, anecdot-
al evidence started to accumulate for a 
range of beneficial health effects and it 
became widely used (without rigorous 
supporting evidence) for the treatment 
of various gynaecological symptoms.2
It became clear that the COCP could 
offer women health benefits in three 
ways: by providing highly effective con-
traception, by treating some gynaeco-
logical symptoms and by preventing 
some gynaecological and medical con-
ditions.3
Health benefits associated with the use 
of hormonal contraceptives have not re-
ceived the same degree of research or 
publicity as have potential adverse ef-
fects, and the quality of evidence for 
such benefits is highly variable. 
Treatment of gynaecological disease
Conditions that may respond to COCP 
treatment are listed in Table I. Prima-
ry dysmenorrhoea is the condition that 
responds best. While most of the evi-
dence for this effect comes from stud-
ies with medium dose (50 µg oestrogen) 
COCPs,4 low dose (20 µg oestrogen) 
COCPs  are likely to have a similar ef-
fect.5  The benefit is probably associat-
ed primarily with the suppression of ovu-
lation.  Secondary dysmenorrhoea due 
Table I:  Evidence for treating symptoms with COCPs*
Symptom
Approximate proportion of suffer-






- Ovulatory dysfunctional  
  uterine bleeding
- Anovulatory dysfunctional
  uterine bleeding
- Coagulopathy
- Uterine fibroids
- Iron deficiency anaemia










Primary dysmenorrhoea 70% (with 50 µg oestrogen COCPs) II
Secondary dysmenorrhoea 40% II
Premenstrual syndrome < 30% III
Acne 30% - 80% (depending on formulation) II
Hirsutism < 10% IV
Other cyclical symptoms Variable IV
to chronic pelvic inflammatory disease 
or endometriosis may also respond, al-
beit to a lesser degree, to COCP treat-
ment. One randomised, open-label study 
reported that the COCP was as effec-
tive as GnRH (Gonadotrophin-Releasing 
Hormone) in reducing dysmenorrhoea 
due to endometriosis, but less effective 
in reducing deep dyspareunia.6
In most women COCPs are also able 
to provide effective control of menstru-
al cycle symptoms such as menorrhagia 
(E2), dysmenorrhoea (E1) and premen-
strual syndrome (E1).
Evidence that the COCPs alleviate 
other cyclical symptoms such as mid-
cycle pain, perimenstrual migraine, 
menstruation-related epilepsy and more 
rare symptoms, is limited. Many of these 
conditions are so uncommon that ran-
domised trials for treatment are not 
feasible. The most effective approach 
to treating these conditions may be the 
continuous use of COCPs (i.e. with no 
monthly break) or the use of a progesto-
gen-only method that inhibits ovulation, 
provided that breakthrough bleeding is 
not a problem. 
Menorrhagia due to ovulatory dys-
functional uterine bleeding usually re-
sponds well to COCP treatment, where-
as the response of menorrhagia caused 
by other conditions is quite variable.7 
The best evidence comes from studies 
with COCPs containing 50 µg oestro-
gen.7 It is not clear whether the same 
level of benefit occurs with the lowest-
dose pills currently available,8 although 
a randomised, placebo controlled, dou-
ble blind trial of COCPs delivering either 
20 µg or 30 µg of oestrogen, has shown 
COCP – combined oestrogen-progestogen oral contraceptive pill.
There have been few randomised controlled trials of the effect of COCPs on these disorders.  Much of the 
evidence comes from case-control and cohort studies, often with older and higher-dose preparations (simi-
lar studies using modern very low-dose (20 µg) COCPs are rare).  
References have not been included for uncommon conditions or weak associations.
NHMRC – National Health and Medical Research Council
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that these dosages significantly reduce 
dysfunctional uterine bleeding.
The use of COCPs tends to raise 
haemoglobin levels, especially in wom-
en with a convincing clinical history of 
menorrhagia, and reduces the severity 
of iron deficiency anaemia.9
Acne responds well to treatment 
with COCPs. The mechanism involves 
partly a decrease in ovarian secretion 
of testosterone, partly an increase in 
the production of sex-hormone-binding 
globulin, and partly anti-androgenic ef-
fects (e.g. with the use of cyproterone 
acetate). Hirsutism is less likely to re-
spond to COCPs and usually requires 
higher doses of an anti-androgen.10
The relationship between ovarian 
hormone production and premenstrual 
syndrome was suggested as early as 
1931 and it has been common practice 
to treat premenstrual syndrome with 
COCPs to inhibit ovulation. However, no 
satisfactory controlled studies support-
ing the effectiveness of this treatment 
have been published.11
COCPs are not as effective in pre-
venting transmission of sexually trans-
mitted infections (STIs) as in preventing 
pregnancy. Although they reduce the 
risk of acute upper genital tract pelvic 
inflammatory disease,12 they do not 
prevent cervical colonisation and those 
women at risk of encountering STIs are 
best advised to use condoms as well as 
COCPs.
Prevention of gynaecological and 
other disease
Possible small associations between 
COCPs and breast or cervical cancer 
have been given extensive publicity.13 
By contrast, the very high degree of pro-
tection offered to COCP users against 
endometrial and ovarian cancer, is 
much less well-known. 
The long-term risk of ovarian cancer 
is reduced by 40% after 4 years of 
COCP use, 54% after 8 years, and 60% 
after 12 years.14 Protection against ovar-
ian and endometrial  cancer continues 
for many years after discontinuation of 
COCP use15 and appears to be related 
to the progestogenic component of the 
pill.16  Case-control studies also show 
reasonably sound evidence that long-
term use of COCPs provides some pro-
tection against the later development of 
uterine fibroids, endometriosis, recurrent 
ovarian cysts, acute pelvic inflammatory 
disease, infertility, iron-deficiency anae-
mia, benign breast lumps, toxic shock 
syndrome, acne and hirsutism.17
There is less substantial evidence 
for beneficial effects in reducing the 
later incidence of thyroid disease, rheu-
matoid arthritis, duodenal ulceration, 
Trichomonas vaginalis infection, and 
in assisting long-term maintenance of 
bone mineral density.
COCP use greatly reduces the risk of 
infertility18 (presumably through protec-
tion against acute pelvic inflammatory 
disease, ectopic pregnancy and endo-
metriosis).  In many of these conditions, 
benefits become more marked with 
longer duration of COCP use.
Evidence of efficacy of COCP in pre-
venting other conditions is summarised 
in Table II.
Conclusion
Modern, very low dose COPC pills, 
have maintained a high degree of 
contraceptive efficacy, but the mar-
gin for error in pill taking appears to 
Table II:  Evidence for preventing gynaecological and other conditions with COCPs
Condition
Relative risk of 
developing condi-
tion after 5 years 
of COCP use
Evidence for 




N H M R C 
level of evi-
dence6
Endometrial cancer 0.4 Strong III-2
Ovarian cancer 0.6 Strong III-2
Colon cancer Evidence confl icting Weak IV
Acute pelvic infl am-
matory disease 0.5 None II
Endometriosis 0.7 Weak III-2
Uterine fi broids 0.8 Strong III-2
Infertility 0.5 Weak III-2
Recurrent ovarian 
cysts 0.5 Weak III-2
Benign breast disease 0.5 Strong III-2
COCP   combined oestrogen-progestogen oral contraceptive pill
Changes in absolute risk cannot be reliably calculated
NHMRC  National Health and Medical Research Council
be much smaller. These COCPs have 
a much lower incidence of side effects 
and serious complications than ear-
ly high dose COCPs.  Serious health 
risks from venous thrombo-embolism 
are rare, and not measurably higher for 
pills containing third-generation pro-
gestogens compared with earlier pro-
gestogens.
Most women feel confident taking 
modern COCPs but myths about these 
drugs still persist. Most non-contracep-
tive health benefits of COCPs are not 
widely appreciated, in spite of much 
evidence. Controversy still persists 
over the association between COCP 
use and breast cancer. Although slight-
ly more breast cancers are detected in 
current COCP users (relative risk 1.24; 
95%CI: 1.15-1.33), they are less ad-
vanced in stage and less aggressive in 
behaviour.  
See CPD Questionnaire, page 34
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